InflaRx (IFRX) Short term Debt (2020 - 2022)

InflaRx (IFRX) posted Short term Debt of $144451.4 for Q3 2022, up 3.86% sequentially from $139078.0 in Q2 2022.

InflaRx (IFRX) Short term Debt (2020 - 2022) Analysis & Trends

InflaRx has reported Short term Debt for 3 years, with the latest figure at $144451.4 in Q3 2022.

Quarterly Short term Debt changed N/A year-over-year to $144451.4 in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $144451.4 (changed N/A YoY) and the FY2021 annual result came in at $163552.6, up 21.67% from the prior year.
Short term Debt climbed to $144451.4 in Q3 2022 per IFRX's latest filing, from $139078.0 in the prior quarter.
Over five years, Short term Debt peaked at $432094.3 in Q1 2021 and troughed at $139078.0 in Q2 2022.
A 3-year average of $187433.8 and a median of $147432.5 in 2022 frame the typical range for Short term Debt.
The sharpest annual moves came in 2021 and 2022: Short term Debt rose 12.64% in 2021, then plunged 65.88% in 2022.
Over 3 years, Short term Debt stood at $140364.7 in 2020, then grew by 12.64% to $158103.6 in 2021, then retreated by 8.63% to $144451.4 in 2022.
According to Business Quant data, Short term Debt over the past three periods registered $144451.4, $139078.0, and $147432.5 for Q3 2022, Q2 2022, and Q1 2022 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	InflaRx	140.30 Mn	-43.96 Mn	2.74 Bn

Download Data